FL-MHPS
15.4.2020 12:02:05 CEST | Business Wire | Press release
Mitsubishi Hitachi Power Systems’ (MHPS) J-Series gas turbine installed fleet today reached one million hours of commercial operation, nearly double that of similar sized gas turbines from competitors. This gas turbine series — the company’s largest and most advanced — leads the industry with reliable, efficient power generation and flexibility to meet rigid new standards for reduced carbon emissions. Introduced in 2011, the J-Series delivers an industry-leading overall reliability of 99.5% and an efficiency greater than 64%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200415005220/en/
Forty-three J-Series gas turbines are in commercial operation, and total ordered capacity exceeds 25 GW globally. One hundred units have been technically selected in Brazil, Canada, Japan, Mexico, Peru, South Korea, Taiwan, Thailand, and the United States.
Donald Schubert, Principal at SHL Consulting LLC and former Senior Vice President of Marshes Global Power Practice, said, “MHPS continues to embrace proven technology throughout their gas turbine fleet. The insurability of the operating units remains at an all-time high for MHPS large frame machines.”
In many parts of the world, the J-Series gas turbine frequently replaces retired coal-fired power generation or is installed as an alternative to coal-fired power generation. Compared to the same size coal-fired power plants, one million J-Series operating hours has resulted in CO2 emissions reduction of 270 million tons. This is equivalent to CO2 emissions from 1,346,918 railcars of coal burned.
Ken Kawai, President and CEO of MHPS said, “As we reflect on the important milestone of achieving one million operating hours with our J-Series gas turbine, we know the most important part of that accomplishment is that we ran all those hours with 99.5% reliability. It all started with T-Point, our own combined cycle power plant in Takasago, Japan. Our extreme reliability is not by good luck. It is because we test the durability and reliability of every new technological advancement for 8,000 hours before shipping it to our customers. We have now built a second T-Point, T-Point 2, where our latest advancement, the cutting-edge air-cooled 60 Hz JAC, has just synced to the grid and achieved full load. Step-by-step, we have developed the largest, most reliable and most fuel-efficient gas turbine in the world.”
Recent innovations to the J-Series target further reductions in carbon emissions. Last month the company received an order from the Intermountain Power Agency, in Delta, Utah, for two JAC gas turbines capable of using up to 30% renewable hydrogen fuel. Eventually, these turbines will be capable of using 100% renewable hydrogen fuel. The 30% hydrogen system will reduce carbon emissions by more than 75% compared to the same size coal-fired power plant, and the 100% hydrogen system will eliminate carbon emissions entirely. MHPS is also developing grid-scale renewable hydrogen production and storage through the Advanced Clean Energy Storage (ACES) project in Delta, Utah.
Paul Browning, President and CEO of MHPS Americas and newly appointed Chief Regional Officer for Europe, Africa and the Middle East, said, “Going forward, every gas turbine MHPS sells globally will have renewable hydrogen fuel capability. This allows our customers to purchase a natural gas power plant today, and convert it over time into a renewable energy storage facility. This gives plant operators flexibility now and into the future to choose what mix of natural gas power generation and renewable energy storage best meets the needs of their electrical grids. We are providing the power generation and storage solutions that enable our customers to combat climate change and advance human prosperity. This is a Change in Power.”
About Mitsubishi Hitachi Power Systems Americas, Inc. Mitsubishi Hitachi Power Systems Americas, Inc. (MHPS Americas), headquartered in Lake Mary, Florida, employs more than 2,000 power generation and energy storage experts and professionals. Our employees are focused on empowering customers to affordably and reliably combat climate change while also advancing human prosperity. MHPS Americas’ expertise includes natural gas, steam, aero-derivative, geothermal, and distributed renewable power generation technologies and services, along with renewable hydrogen and battery energy storage systems, environmental control systems solutions, and digital solutions enabling autonomous operations and maintenance of power assets throughout North and South America. MHPS Americas is a subsidiary of Mitsubishi Hitachi Power Systems (MHPS), a joint venture between Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in power generation systems. Learn more about MHPS by visiting www.changeinpower.com . |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200415005220/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
